ReviewEuropean respiratory review : an official journal of the European Respiratory Society2026
The impact of elexacaftor-tezacaftor-ivacaftor on cardiometabolic risk factors: a systematic review.
Review in European respiratory review : an official journal of the European Respiratory Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Elexacaftor-tezacaftor-ivacaftor (ETI) is a highly effective modulator therapy associated with significant improvements in respiratory function and quality of life among people living with cystic fibrosis (CF). However, ETI has also been shown to result in significant weight gain and there is emerging interest regarding traditional cardiometabolic risk factors. This systematic review investigated the effects of ETI on cardiometabolic risk factors (obesity/overweight, body composition, glucose metabolism, lipids, blood pressure and bone parameters) in people living with CF. This review adhered with Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) guidelines and was registered in PROSPERO (CRD42025630118). The following databases were searched in December 2024 and June 2025: PubMed, Scopus, Web of Science and Embase. A total of 54 publications met inclusion criteria (including ETI treatment duration >4 months, >10 total participants, empirical studies) and underwent data extraction. Risk of bias was assessed using National Institutes of Health tools. Results were prepared in tabular format and narrative summary. There was notable heterogeneity in study design and results. In published studies to date, ETI initiation was generally followed by a decrease in glycated haemoglobin, but minimal change in other glycaemic or insulinaemic parameters. Some studies reported increased blood pressure, hypertension and overweight/obesity classification, and cholesterol levels. The observational design and short duration of most studies limit the ability to conclude direct effects of ETI, particularly in the long term. However, we conclude there is likely increased risk of certain traditional cardiometabolic risk factors in ageing people with CF, thus highlighting the importance of clinical surveillance and prompt intervention if needed.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.